Athira Pharma, Inc. Stock News

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence

Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small molecule positive modulators of HGF/MET reverse me

BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt

BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

Upgrades For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co

U.S. stock indexes end lower Wednesday, giving back earlier gains, after Federal Reserve Chairman Jerome Powell reiterated plans for combating inflation, in Capitol Hill testimony.

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday. The Dow traded up 0.50% to 30,682.21 while the NASDAQ rose 0.75% to 11,152.83. The S&P a

Its mid-stage clinical trial failed to help patients with Alzheimer's.

Shares of Athira Pharma Inc. apha plummeted 66.9% toward a record low in active afternoon trading Wednesday, enough to make them the biggest decliners trading on major market indexes, after the biopha

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer's trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 da

Its mid-stage clinical trial failed to help patients with Alzheimer's.

Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. The post Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Res

Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-mo

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health